Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants

SIMPLE SUMMARY: In our study, we retrospectively collected data of patients with germline CDKN2A pathogenic variants who received targeted therapy for advanced melanoma across four European centers. Since loss of CDKN2A function may intrinsically limit the activity of MAPK-directed targeted therapy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Spagnolo, Francesco, Dalmasso, Bruna, Tanda, Enrica, Potrony, Miriam, Puig, Susana, van Doorn, Remco, Kapiteijn, Ellen, Queirolo, Paola, Helgadottir, Hildur, Ghiorzo, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157545/
https://www.ncbi.nlm.nih.gov/pubmed/34069952
http://dx.doi.org/10.3390/cancers13102440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157545/
https://www.ncbi.nlm.nih.gov/pubmed/34069952
http://dx.doi.org/10.3390/cancers13102440

Ejemplares similares